New cancer drug GEN1057 tested in early trial – but study stopped early
NCT ID NCT06573294
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new antibody drug called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see how the drug behaves in the body. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
National Cancer Center, Tsukiji 5-1-1
Tokyo, Japan
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
Start Madrid Centro Integral Oncologico Clara Campal CIOCC
Madrid, 28050, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral drug elraglusib aims to tame advanced solid tumors
- Engineered virus targets Hard-to-Treat cancers from the inside
- New drug combo targets Hard-to-Treat cancers
- Engineered herpes virus takes aim at Hard-to-Treat cancers
- Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
- New drug combo takes on advanced cancers